S
Stephan Reichenbach
Researcher at University of Bern
Publications - 113
Citations - 12123
Stephan Reichenbach is an academic researcher from University of Bern. The author has contributed to research in topics: Osteoarthritis & Randomized controlled trial. The author has an hindex of 46, co-authored 104 publications receiving 10808 citations. Previous affiliations of Stephan Reichenbach include University of Bristol & Boston University.
Papers
More filters
Journal ArticleDOI
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Christoph Stettler,Christoph Stettler,Simon Wandel,Sabin Allemann,Adnan Kastrati,Marie Claude Morice,Albert Schömig,Matthias Pfisterer,Gregg W. Stone,Martin B. Leon,José Suárez de Lezo,Jean-Jacques Goy,Seung-Jung Park,Manel Sabaté,Maarten J. Suttorp,Henning Kelbæk,Christian Spaulding,Maurizio Menichelli,Paul Vermeersch,Maurits T. Dirksen,Pavel Cervinka,Anna Sonia Petronio,Alain J Nordmann,Peter Diem,Bernhard Meier,Marcel Zwahlen,Stephan Reichenbach,Sven Trelle,Stephan Windecker,Peter Jüni,Peter Jüni +30 more
TL;DR: A network meta-analysis with a mixed-treatment comparison method to combine direct within-trial comparisons between stents with indirect evidence from other trials while maintaining randomisation found sirolimus-eluting stents seem to be clinically better than bare-metal and paclitaxel-eluted stents.
Journal ArticleDOI
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.
Sven Trelle,Stephan Reichenbach,Simon Wandel,Pius Hildebrand,Beatrice Tschannen,Peter M. Villiger,Matthias Egger,Peter Jüni +7 more
TL;DR: Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms, and Naproxen seemed least harmful.
Journal ArticleDOI
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Peter Jüni,Linda Nartey,Stephan Reichenbach,Stephan Reichenbach,Rebekka Sterchi,Paul Dieppe,Matthias Egger,Matthias Egger +7 more
TL;DR: The findings indicate that rofecoxib should have been withdrawn several years earlier and the reasons why manufacturer and drug licensing authorities did not continuously monitor and summarise the accumulating evidence need to be clarified.
Journal ArticleDOI
Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review and Meta-analysis
TL;DR: In patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events.
Journal ArticleDOI
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study.
TL;DR: Patients with osteoarthritis are at higher risk of death compared with the general population, and history of diabetes, cancer, or cardiovascular disease and the presence of walking disability are major risk factors.